Business Wire

Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, and ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Business Wire

First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective ...